JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune‐Mediated Inflammatory Arthritis in Rats
International Journal of Rheumatic Diseases · 2026-07 · 29 (7)
DOI: 10.1111/1756-185x.70773 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 15.07.2026. Verfasst von Zhiming Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Osteogenesis, Piperidines, Pyrimidines, Arthritis, Experimental. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fujian Provincial Education Research Project for Young and Middle-aged Teachers (Science and Technology), Fujian Provincial Natural Science Foundation Project, Guangzhou Science and Technology Program Key Project.
Abstract (Originalsprache)
Objective
This study sought to investigate the mechanism by which tofacitinib affects inflammatory response and osteogenic differentiation in immune‐mediated inflammatory arthritis in rats in relation to Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3).
Methods
Wistar male rats were induced by the combination of bovine proteoglycan and incomplete/complete Freund's adjuvant to establish the immune‐mediated inflammatory arthritis model. The clinical manifestations were observed. Hematoxylin and eosin staining was used to evaluate pathological changes in sacroiliac joints and surrounding cartilage. Additionally, the levels of osteogenic differentiation‐related proteins, serum inflammatory factors, and alkaline phosphatase (ALP) were measured. Flow cytometry was conducted to analyze the proportion of Th17 cells in peripheral blood. Alizarin red staining detected the osteogenic differentiation of ligament fibroblasts.
Results
The rats exhibited joint swelling, inflammatory infiltration in the sacroiliac joint, and cartilage destruction after modeling. Elevations were also detected in the levels of serum pro‐inflammatory factors, the proportion of Th17 cells, ALP activity, phosphorylated (p)‐JAK1/2, p‐STAT3, osteogenic differentiation markers in ligament fibroblasts, as well as in the mineralized nodules. Tofacitinib intervention inhibited the phosphorylation of JAK and STAT3, downregulated bone differentiation‐related proteins, decreased the mineralized nodules, reduced the activity of ALP, and decreased the levels of pro‐inflammatory factors. However, the combined use of the STAT3 agonist Colivelin partially reversed the inhibitory effect of tofacitinib on joint inflammation and osteogenic differentiation.
Conclusion
Tofacitinib alleviated the inflammatory response in immune‐mediated inflammatory arthritis and inhibited osteogenic differentiation in rats via inhibition of the JAK/STAT3 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Fuzhou, Fujian, China.
- Department of Rheumatology and Immunology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Department of Preventive Treatment of Disease, The Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Department of Rheumatology and Immunology, Sanming Integrated Traditional Chinese and Western Medicine Hospital, Sanming, Fujian, China.
- Department of Clinical Laboratory Medicine, The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Fuzhou, Fujian, China.
- Department of Spinal Surgery, The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Fuzhou, Fujian, China.
ORCID-Profile: Feng Zheng
Förderung
- Fujian Provincial Education Research Project for Young and Middle-aged Teachers (Science and Technology)
- Fujian Provincial Natural Science Foundation Project
- Guangzhou Science and Technology Program Key Project
Zitieren
APA
Zhang, Z., Lin, Z., Hu, G., Huang, Q., Xu, C., Zhang, J., Wu, F., Song, R., Chen, H., & Zheng, F. (2026). JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune‐Mediated Inflammatory Arthritis in Rats. International Journal of Rheumatic Diseases, 29(7). https://doi.org/10.1111/1756-185x.70773
Vancouver
Zhang Z, Lin Z, Hu G, Huang Q, Xu C, Zhang J, et al. JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune‐Mediated Inflammatory Arthritis in Rats. International Journal of Rheumatic Diseases. 2026;29(7). doi:10.1111/1756-185x.70773
BibTeX
@article{Zhang2026,
author = {Zhang, Zhiming and Lin, Zhiming and Hu, Genlian and Huang, Qingqing and Xu, Congrong and Zhang, Jiafang and Wu, Fangzhen and Song, Rongbin and Chen, Hongshan and Zheng, Feng},
title = {JAK Inhibitor Tofacitinib Ameliorates Inflammation Response and Osteogenic Differentiation in Immune‐Mediated Inflammatory Arthritis in Rats},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {7},
doi = {10.1111/1756-185x.70773}
}
EUVIMED